Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

Understanding EoE

About EoE

EVEN IF YOUR PATIENTS SAY THEY ARE FINE, EoE IS A CHRONIC, PROGRESSIVE TYPE 2 INFLAMMATORY DISEASE

EoE requires lifelong follow-up to ensure treatment adherence and efficacy, limit long-term complications, and reduce need for dilations1-3

DISABLING SYMPTOMS

Adult and adolescent patients with EoE experience1,4-6:

  • Dysphagia
  • Noncardiac chest pain
  • Food impaction and subsequent bolus removal
  • Regurgitation

TREATMENT DELAYS

  • 6 YEARS median diagnostic delay from symptom onset7
  • ≤2 YEARS of diagnostic delay; 88% of patients experienced inflammation-driven changes and/or increased fibrosis7
  • 8% increased risk of fibrostenosis every year7
  • 26% increased risk in stricture for each year of gap in treatment8
  • Gap in care: Only ~1 in 5 patients undergo biopsy at the time of EFI (47% of those biopsied are diagnosed with EoE)9

UNDERLYING INFLAMMATION

~75% of EoE patients have at least one coexisting atopic type 2 inflammatory disease3,10:

  • Allergic rhinitis
  • Asthma
  • Atopic dermatitis
  • Food allergies

EFI, esophageal food impaction; EoE, eosinophilic esophagitis.


LIVING WITH EoE PLACES A HIGH BURDEN ON BOTH ADULTS AND ADOLESCENTS

High EoE-associated emotional and psychological burden and perceived stigma contribute to a poor HRQoL11,a

Group 1000004030

a Web survey in adolescents (n=211; caregiver-reported) and adults (n=184). 
 
HRQoL, health-related quality of life.

References:

  1. Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ. Health-related quality of life and costs associated with eosinophilic esophagitis: a systematic review. Clin Gastroenterol Hepatol. 2018;16(4): 495-503.e8.doi:10.1016/j.cgh.2017.06.036
  2. Chehade M, Jones SM, Pesek RD, et al. Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the Consortium for Food Allergy Research. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.e5. doi:10.1016/j.jaip.2018.05.038
  3. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1)35-50. doi:10.1038/nrd4624
  4. D'Allessandro A, Esposito D, Pesce M, Cuomo R, De Palma GD, Sarnelli G. Eosinophilic esophagitis: from pathophysiology to treatment. World J Gastrointest Pathophysiol. 2015;6(4):150-158. doi:10.4291/wjgp.v6.i4.150
  5. Li-Kim-Moy JP, Tobias V, Day AS, Leach S, Lemberg DA. Esophageal subepithelial fibrosis and hyalinization are features of eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2011;52(2):147-153: doi:10.1097/MPG.0b013e3181ef37a1
  6. Straumann A, Bussmann C, Zuber M, Vannini S, Simon HU. Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol. 2008;6(5):598-600. doi:10.1016/j.cgh.2008.02.003
  7. Schoepfer AM, Safroneeva E, Bussman C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in time-dependent manner. Gastroenterology. 2013;145(6):1230-6.e1-2 doi:10.1053/j.gastro.2013.08.015
  8. Chang NC, Thakkar KP, Ketchem CJ, Eluri S, Reed CC, Dellon ES. A gap in care leads to progression of fibrosis in eosinophilic esophagitis patients. Clin Gastroenterol Hepatol. 2022;20(8):1701-1708.e8. doi:10.106/j.cgh.2021.10.028
  9. Redd WD, Dellon ES, Bekal P, et al. Real-world study of biopsy practices during food impactions in the emergency department: multi-state GI practice. Presented at: 2025 American College of Gastroenterology (ACG) Annual Meeting: Phoenix, AZ, USA; October 24-29, J Clin Gastroenterol. 2017;51(8):659-668. doi:10.1097/mcg.00000000000000879
  10. van Rhijn BD, Bredenoord AJ. Management of eosinophilic esophagitis based on pathophysiological evidence.  J Clin Gastroenterol. 2017;51(8):659-668. doi:10.1097/MCG.0000000000000879
  11. Gold BD, Goodwin B, Davis K, et al. Health-related quality of life and perceived stigma in eosinophilic esophagitis: a real-world, US, web-based survey. Gastro Hep Adv. 2024;3:1087-1097. doi:1016/j.gastha.2024.07.0

EoE IS A CHRONIC, PROGRESSIVE TYPE 2 INFLAMMATORY DISEASE AFFECTING PATIENTS AS YOUNG AS 1 YEAR OLD

EoE requires lifelong follow-up to ensure treatment adherence and efficacy, limit long-term complications, and reduce the need for esophageal dilations1-3


DISABLING DISEASE BURDEN

Children with EoE experience1:

  • Abdominal pain and vomiting
  • Weight loss, impaired growth, and failure to thrive
  • Adaptive behaviors to deny or mask symptoms
  • Coexisting atopic type 2 inflammatory diseases


URGENCY FOR EARLY DIAGNOSIS

  • Delay in diagnosing and treating EoE can impact childhood growth2
  • Early diagnosis improves HRQoL and may slow disease progression1
  • Patients achieving histologic remission experienced 77% reduction in stricture development3

CHILDREN AND CAREGIVERS NEED A THERAPY THAT TREATS THE UNDERLYING 
TYPE 2 INFLAMMATION DRIVING EoE

EoE, eosinophilic esophagitis; HRQoL, health-related quality of life.

References:

  1. Muir AB, Brown-Whitehorn T, Godwin B, Cianferoni A. Eosinophilic esophagitis: early diagnosis is the key. Clin Exp Gastroenterol. 2019;12:391-399. doi:10.2147/CEG.S175061
  2. Chehade M, Hiremath GS, Zevit N, et al. Disease burden and spectrum of symptoms that impact quality of life in pediatric patients with eosinophilic esophagitis. Gastro Hep Adv. 2024;3(8):1054-1068. doi:10.106/j.gastha.2024.08.009
  3. Strauss Starling A, Ren Y, Li H, et al. Reducing eosinophil counts in eosinophilic esophagitis in children is associated with reduction in later stricture development. Am J Gastroenterol. 2024;119(10):2002-2009. doi:10.14309/ajg.0000000000000002830


Progression

UNCONTROLLED EoE LEADS TO LONG-TERM DAMAGE, LEAVING ADULTS AND ADOLESCENTS AT RISK, EVEN IF THEY SAY THEY ARE FINE

Assess treatment adherence and efficacy regularly to ensure esophageal healing and inactive EoE, reducing long-term complications and the need for future dilations1

Group 1000003664

a Multicenter study in 269 patients aged ≥17 years.
b Retrospective study in 200 adult patients, responders to TCS.

EoE, eosinophilic esophagitis; TCS, topical corticosteroids.

References:

  1. Saravino EV, Fassan M, de Bortoli N, et al. Italian EoExpert panel recommendation for disease control, switching criteria, and follow-up in eosinophilic esophagitis from pediatric to adult age. Ther Adv Gastroenterol. 2025;18:17562848251337515. doi:10.1177/17562848251337515
  2. Safroneeva E, Straumann A, Schoepfer AM. Latest insights on the relationship between symptoms and biologic findings in adult with eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2028;28(1)35-45. doi:10.106/j.giec.2017.08.001
  3. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013.145(6):1230-1236.e1-2. doi:10.1053/j.gastro.2013.08.015
  4. Chang NC, Thakkar KP, Ketchem CJ, et al. A gap in care leads to progression of fibrosis in eosinophilic esophagitis patients. Clin Gastroenterol Hepatol. 2022;20(8):1701-1708.e2. doi:10.106/j.cgh.2021.10.028

UNCONTROLLED EoE LEADS TO LONG-TERM DAMAGE, LEAVING CHILDREN AT RISK

Assess treatment adherence and efficacy regularly to ensure esophageal healing and inactive EoE,
reducing long-term complications and the need for future dilations1

Group 1000003814

a In this meta-analysis, histologic remission was defined as <5 EOS/HPF, whereas international guidelines and DUPIXENT trials define remission as ≤6 EOS/HPF.
b Retrospective study in 200 adult patients, responders to TCS.

EoE, eosinophilic esophagitis; EOS/HPF, eosinophils per high-power field; PPIs, proton pump inhibitors; TCS, topical corticosteroids.

References:

  1. Saravino EV, Fassan M, de Bortoli N, et al. Italian EoExpert panel recommendation for disease control, switching criteria, and follow-up in eosinophilic esophagitis from pediatric to adult age. Ther Adv Gastroenterol. 2025;18:17562848251337515. doi:10.1177/17562848251337515
  2. Lucendo AJ, Gutierrez-Ramirez L, Tejera-Munoz A, et al. Proton pump inhibitors for inducing and maintaining remission in eosinophilic esophagitis: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025;23(12):2115-2127.e21. doi:10.1016/j.cgh.2025.01.016
  3. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013.145(6):1230-1236.e1-2. doi:10.1053/j.gastro.2013.08.015
  4. Chang NC, Thakkar KP, Ketchem CJ, et al. A gap in care leads to progression of fibrosis in eosinophilic esophagitis patients. Clin Gastroenterol Hepatol. 2022;20(8):1701-1708.e2. doi:10.106/j.cgh.2021.10.028


Adaptive Behaviors

~3 IN 4 EoE PATIENTS USED AT LEAST 1 ADAPTIVE BEHAVIOR DAILY TO COPE WITH SYMPTOMS

88% of patients used at least 1 adaptive behavior per week1,a

ADAPTIVE BEHAVIORSQUESTIONS
When eating, patient may compensate by2,3:
 I = Imbibing fluids with mealsWhen you eat, do you need a drink to help swallow? How much sauce or condiments do you use?
M = Modifying foodsDo you cut your food into smaller pieces than others when you eat?
P = Prolonging meal timesAre you typically the last one to finish a meal?
A = Avoiding hard texture foodsDo you avoid certain foods (eg. chicken, steak, rice, bread)?
C = Chewing excessivelyDo you notice that you have to chew more or longer than others when you eat? Do others notice it?
T = Turning away tablets/pillsDo you avoid taking tablets or pills?
S = Social impairmentHow often do you go out to eat? Do you ever make excuses to avoid eating in public?

IDENTIFY ADAPTIVE BEHAVIORS: THEY ARE A SIGN TO  FURTHER ASSESS 
ENDOSCOPY AND HISTOLOGY

a Based on a retrospective analysis from 2 US databases (n=234).

EoE, eosinophilic esophagitis.

References:

  1. Chehade M, Pandit-Abid N, Raphael BP, et al. Cross-sectional real-world survey of adult patients with eosinophilic oesophagitis: symptom burden and adaptive behaviors. Presented at: European Academy of Allergy and Clinical Immunology (EAACI 2025), June 13-16, Glasgow, United Kingdom.
  2. Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840-851. doi:10.1053/j.gastro.2019.09.052
  3. Larsson H, Strobel MJ, Perez-Guagnelli E. Emotional journey of patients with eosinophilic esophagitis. Adv Ther. 2023;40(12):5254-5270. doi:10.1007/s12325-023-02678-9

UNCOVER ADAPTIVE BEHAVIORS CHILDREN USE TO COPE

Eating behaviors in pediatric patients with EoE evolve with age, making it challenging for providers to unmask them1

VARIABLESINFANTS OR TODDLERSGRADE SCHOOL
Duration of
meals
  • Longer than siblings or rest of family
  • Often leaves and comes back to the table
  • Grazes on small volumes of liquid or food
  • Longer than friends
  • Returns from school with full lunchbox
Coping
behaviors
  • Preference for liquids and soft foods
  • Pockets food in cheek for prolonged periods and/or spits food out; dips foods in liquid
  • Uses large amounts of dips, sauces, condiments, and other liquids to help swallowing (narrow range of preferred foods sometimes)
  • Prolonged chewing of food
Food selection
  • Difficulty advancing diet from pureed baby food
  • Demonstrates feeding refusal or fussy behavior during meals
  • Difficulty or refusal to expand diet with new flavors, types of foods, or textures

IDENTIFY ADAPTIVE BEHAVIORS: THEY ARE A SIGN TO FURTHER ASSESS ENDOSCOPY AND HISTOLOGY1 

EoE, eosinophilic esophagitis.

Reference:

  1. Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840-851. doi:10.1053/j.gastro.2019.09.052


Control

MANY ADULT PATIENTS WITH EoE SUFFER FROM INADEQUATE DISEASE CONTROL WITH PPIs, TCS, AND ELIMINATION DIETS

Achieving control is a key treatment goal in EoE  

FAILURE TO ACHIEVE HISTOLOGIC RESPONSE/REMISSION WITH PPIs/TCS/ELIMINATION DIETS

  • Only half of patients achieved histologic response (<15 EOS/HPF) across 4 EU countries (DE, IT, SP, UK) during the first 5 years of EoE diagnosis1
  • ~63% of patients on PPIs failed to achieve histologic remission (medical follow-up of 4 months)2  
     

HISTOLOGIC RELAPSE AND SYMPTOM RECURRENCE ON PPIs/TCS

  • In ~1 in 3 patients, PPIs failed to maintain histologic response (median follow-up of 11.7 months)2
  • 61% of patients on TCS showed histological relapse despite continuous treatment (median follow-up of 4-12 months)3,a
  • 78% of patients showed histological relapse within 1 year after stopping treatment4,b
  • ~57% of patients showed symptom recurrence after stopping TCS (median 8 months)4,c 

MANY PATIENTS ON PPIs OR TCS MAY BE UNCONTROLLED, EVEN IF THEY SAY THEY ARE FINE  
 

PATIENTS ON TCS CONTINUED TO PROGRESS TO STRICTURE FORMATION WITHIN A 3-YEAR PERIOD. STRICTURE FORMATION INCREASES THE RISK OF FOOD IMPACTION AND THE REQUIREMENT FOR DILATION5-7 

a Retrospective study of 55 adults with EoE with initial response to TCS, 33 of whom had ≥2 follow-up endoscopies.
b Study in 58 patients with histologic response (<15 EOS/HPF) to TCS who discontinued treatment. 33 of them had symptom recurrence within 1 year after stopping treatment, of which 78% had histologic relapse (≥15 EOS/HPF).
c Study in 58 patients with histologic response (<15 EOS/HPF) to TCS who discontinued treatment. 57% had symptom recurrence after a median of 244 days (8 months).

EoE, eosinophilic esophagitis; EOS/HPF, eosinophils per high-power field; PPIs, proton pump inhibitors; TCS, topical corticosteroids.

References:

  1. von Arnim U, Zerbib F, Radwan A, et al. Treatment patterns and disease progression among patients with eosinophilic oesophagitis in Europe: a real-world study. Poster PP0085 presented at United European Gastroenterology-2024 (UEGW-2024), October 12-15, Vienna (Messe Wien) Austria
  2. Lucendo AJ, Gutierrez-Ramirez L, Tejera-Munoz A, et al. Proton pump inhibitors for inducing and maintaining remission in eosinophilic esophagitis: an updated systemic review and meta analysis. Clin Gastroenterol Hepatol. 2025;23(12):2115-2127.e21. doi:10.1015/j.cgh.2025.01.016
  3. Eluri S, Runge TM, Hansen J, et al. Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI non-responsive eosinophilic esophagitis. Clin Transl Gastroenterol. 2017;8(6):e97. doi:10.1038/ctg.2017.27
  4. Dellon ES, Gupta SK. Clin Gastroenterol Hepatol. 2019:17(11)2149-2160. doi:10.1016/j.cgh.2019.01.030
  5. Hirano I, Pandolfino JR, Boeckxstaens GE. Functional lumen imaging probe for the management of esophageal disorders: expert review from clinical practice updates committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017;15(3):325-334. doi:10.1018/j.cgh.2016.10.022
  6. Nicodeme F, Hirano I, Chen J, et al. Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2013;11(9):1101-1107. c1.doi:1016/j.cgh.2013.03.020
  7. Greuter T, Godat A, Ringel A, et al. Effectiveness and safety of high- vs low-dose swallowed topical steroids for maintenance treatment of eosinophilic esophagitis: a multicenter observational study. Clin Gastroenterol Hepatol. 2021;19(12):2514-2523. doi:10.1016/j.cgh.2020.08.27

MANY CHILDREN WITH EoE ARE LEFT UNCONTROLLED WITH 
PPIs, TCS, AND ELIMINATION DIETS

Achieving control is a key treatment goal in EoE

FAILURE TO ACHIEVE HISTOLOGIC REMISSION ON PPIs

  • ~69% of children on PPIs failed to achieve histologic remission1,a
     

HISTOLOGIC RELAPSE AND SYMPTOM RECURRENCE ON PPIs/TCS

  • Up to 54% of children can achieve remission with PPIs, but ~30% relapse if high-dose PPIs are reduced2
  • 27% of children failed to maintain remission with TCS at 3 months3

SAFETY CONCERNS WITH PPIs/TCS

  • Although generally safe, PPIs raise concerns about the potential negative effects of PPIs on the microbiomes of children2,3
  • TCS use is associated with candidiasis and may lead to adrenal suppression2,4
  • Coexisting conditions such as asthma, AR, and AD in children may require long-term CS cumulative dose, which may impact their growth4

MANY PATIENTS MAY NOT ACHIEVE DISEASE CONTROL WITH PPIs AND TCS

EFFECTIVE EoE TREATMENT IS IMPORTANT TO PREVENT ESOPHAGEAL REMODELING AND STRICTURE FORMATION5

a Data from a meta-analysis of 8 studies including 806 patients <18 years of age.

AD, atopic dermatitis; AR, allergic rhinitis; CS, corticosteroids; EoE, eosinophilic esophagitis; PPIs, proton pump inhibitors; TCS, topical corticosteroids.

References:

  1. Lucendo AJ, Gutierez-Ramirez L, Tejera-Munoz A, et al. Proton pump inhibitors for inducing and maintaining remission in eosinophilic esophagitis: an updated systemic review and meta-analysis. Clin Gastroenterol Hepatol. 2025;23(12):2115-2127.e21. doi:10.1016/j.cgh.2025.01.016
  2. Chehade M, Hiremath GS, Zevit N, et al. Disease burden and spectrum of symptoms that impact quality of life in pediatric patients with eosinophilic esophagitis. Gastro Hep Adv. 2024;3(8):1054-1068. doi:10.1016/j.gastha.2024.08.009
  3. Oliva S, Arrigo S, Bramuzzo M, et al. Eosinophilic esophagitis in children and adolescents: a clinical practice guideline. Ital J Pediatr. 2025;51(1):242. doi:10.1186/s13052-025-02056-x
  4. Chehade M, Katzka DA, Nager S. Thomas RB, Tilton ST. Medical Research Group. A real-world study of cumulative steroid burden among patients with eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol. 2025;23(9):1665-1667.e3. doi:10.1016/f.cgh.2025.01.030
  5. Amil-Dias J, Oliva S, Papadopoulou A, et al. Diagnosis and management of eosinophilic esophagitis in children: an update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024;79(2):394-437. doi:10.1002/jpn.3.12188


WE CAN DO MORE THAN FINE—PATIENTS WITH EoE NEED A TREATMENT APPROACH THAT HELPS THEM ACHIEVE FULL DISEASE CONTROL

High EoE-associated emotional and psychological burdens and perceived stigma contribute to poor HRQoL1-3

Group 1000004016

FAILURE IN ANY DOMAIN AT THREE MONTHS WARRANTS A SWITCH TO A BIOLOGIC1

DSQ, Dysphagia Symptom Questionnaire; EoE-HSS, Eosinophilic Esophagitis Histologic Scoring System; EoE-IQ, EoE Impact Questionnaire; EoE-QoL-A, EoE Quality of Life Questionnaire for Adults; EOS, eosinophils; EREFS, Endoscopic Reference Score; HPF, high-power field; HRQoL, health-related quality of life; PEESS, Pediatric Eosinophilic Esophagitis Symptom Score; PEIS, Pediatric EoE Impact Scale; PESQ-C, Pediatric EoE Signs/Symptoms Questionnaire-Caregiver; PGIC, Patient Global Impression of Change of Dysphagia; PGIS, Patient Global Impression of Severity of Dysphagia.

References:

  1. Gold BD, Goodwin B, Davis K, et al. Health-related quality of life and perceived stigma in eosinophilic esophagitis: a real-world US, web-based survey. Gastro Hep Adv. 2025;3:1086-1097. doi:10.1016/j.gastha.2024.07.0
  2. Dellon ES, Gupta SK. A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2019;17(11):2149-2160. doi:10.1016/j.cgh.2019.01.030
  3. Savarino EV, Fassan M, de Bortoli N, et al. Italian EoExpert panel recommendation for disease control, switching criteria, and follow-up in eosinophilic esophagitis from pediatric to adult age. Ther Adv Gastroenterol. 2025;18:17562848251337515. doi:10.1177/1756284251337515

EVEN WHEN THEY SAY THEY ARE FINE, MANY EoE PATIENTS REMAIN UNCONTROLLED

Do you see these uncontrolled EoE patients?

PARTIALLY CONTROLLED ON PPIs/TCS

ASYMPTOMATIC WITH ACTIVE EoE

 ADAPTIVE BEHAVIORS

Not real patients.


Assessing EoE

MASTERING EoE THROUGH MULTIDIMENSIONAL CARE

Optimizing EoE care through Symptom Control, Observation, and Patho-Evaluation (S.C.O.P.E.)1

Group 1000003266

EoE-HSS, eosinophilic esophagitis histology scoring system; EOS/HPF, eosinophils per high-power field; EREFS, Endoscopic Reference Score; I.M.P.A.C.T.S., Imbibing fluids with meals, Modifying foods, Prolonging meal times, Avoiding hard texture foods, Chewing excessively, Turning away tablets/pills, Social impairment; PPIs, proton pump inhibitors; TCS, topical corticosteroids.

References:

  1. Savarino EV, Fassan M, de Bortoli N, et al. Italian EoExpert panel recommendation for disease control, switching criteria, and follow-up in eosinophilic esophagitis from pediatric to adult age. Ther Adv Gastroenterol. 2025;18:17562848251337515. doi:10.1177/1756284251337515
  2. Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840-851. doi:10.1053/j.gastro.2019.09.052
  3. de Rooij WE, Evertsz FB, Lei A, Bredenoord AJ. General well-being and coping strategies in adult eosinophilic esophagitis patients. J Neurogastroenterol Motil. 2022;28(3):390-400. doi:10.5056/jnm21143
  4. Muir AB, Brown-Whitehorn T, Godwin B, Cianferoni A. Eosinophilic esophagitis: early diagnosis is the key. Clin Exp Gastroenterol. 2019;12:391-399. doi:10.2147/CEG.S175061
  5. Dellon ES, Gupta SK. A conceptual approach to understanding treatment response in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(11):2149-2160. doi:10.1016/j.cgh.2019.01.030
  6. von Armin U, Zerbib F, Radwan A, et al. Treatment patterns and disease progression among patients with eosinophilic oesophagitis in Europe: A real-world study. Poster PP0085 presented at United European Gastroenterology-2024 (UEGW-2024), October 12-15, Vienna (Messe Wien), Austria.

MASTERING EoE THROUGH MULTIDIMENSIONAL CARE

Optimizing EoE care through Symptom Control, Observation, and Patho-Evaluation (S.C.O.P.E.)1

Group 1000004084

EoE-HSS, eosinophilic esophagitis histology scoring system; EOS/HPF, eosinophils per high-power field; EREFS, Endoscopic Reference Score; I.M.P.A.C.T.S., Imbibing fluids with meals, Modifying foods, Prolonging meal times, Avoiding hard texture foods, Chewing excessively, Turning away tablets/pills, Social impairment.

References:

  1. Savarino EV, Fassan M, de Bortoli N, et al. Italian EoExpert panel recommendation for disease control, switching criteria, and follow-up in eosinophilic esophagitis from pediatric to adult age. Ther Adv Gastroenterol. 2025;18:17562848251337515. doi:10.1177/1756284251337515
  2. Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840-851. doi:10.1053/j.gastro.2019.09.052
  3. de Rooij WE, Evertsz FB, Lei A, Bredenoord AJ. General well-being and coping strategies in adult eosinophilic esophagitis patients. J Neurogastroenterol Motil. 2022;28(3):390-400. doi:10.5056/jnm21143
  4. Wechsler JB, Bolton SM, Amsden K, Wershil BK, Hirano I, Kagalwalla AF. Eosinophilic esophagitis reference score accurately identifies disease activity and treatment effects in children. Clin Gastroenterol Hepatol. 2018;16(7)1056-1063. doi:10.1016/j.cgh.2017.12.019
  5. Muir AB, Brown-Whitehorn T, Godwin B, Cianferoni A. Eosinophilic esophagitis: early diagnosis is the key. Clin Exp Gastroenterol. 2019;12:391-399. doi:10.2147/CEG.S175061
  6. Dellon ES, Gupta SK. Clin Gastroenterol Hepatol. 2019;17(11):2149-2160. doi:10.1016/j.cgh.2019.01.030
  7. von Armin U, Zerbib F, Radwan A, et al. Treatment patterns and disease progression among patients with eosinophilic oesophagitis in Europe: A real-world study. Poster PP0085 presented at United European Gastroenterology-2024 (UEGW-2024), October 12-15, Vienna (Messe Wien), Austria.

HOW TO DO MORE: GO BEYOND SYMPTOMS WITH HISTOLOGY AND ENDOSCOPY

Blood biomarkers are still lacking in clinical practice or are inaccurate (blood eosinophil level does not correlate with esophageal eosinophil count or disease activity)1,2

ONLY ENDOSCOPY + BIOPSY CAN REVEAL HIDDEN PROGRESSION4

COLLABORATION MATTERS BETWEEN GASTROENTEROLOGISTS AND PATHOLOGISTS

Making an accurate diagnosis with a complete pathology report (including EoE-HSS when possible) may provide new insights on EoE pathophysiology and on the progression of the disease5

EoE WARRANTS HOLISTIC MANAGEMENT5

EoE-HSS, eosinophilic esophagitis histology scoring system; PEC, peak eosinophil count.

References:

  1. Noble SL, Tyrrell R, Mules TC, Inns S. Non-invasive biomarkers to diagnose and monitor eosinophilic esophagitis: a systemic review. Front Med (Lausanne). 2025;12:1607306. doi:10.3389/fmed.2025.1607306
  2. Chehade M, Falk GW, Aceves S, et al. Examining the role of type 2 inflammation in eosinophilic esophagitis. Gastro Hep Adv. 2022;1(5):720-732. doi:10.1016/j.gastha.2022.05.004
  3. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335-358. doi:10.1177/2050640616689525
  4. Aceves SS, Alexander JA, Baron TH, et al. Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference. Gastrointest Endosc. 2022;96(4):576-592.e1. doi:10.1016/j.gie.2022.05.013
  5. Salvatore S. Eosinophilic esophagitis: when pathologists make the difference. J Pediatr (Rio J). 2022;98(1):1-3. doi:10.1016/j.ped.2021.08.001

Dupixent API

MAT-SA-2600496/v1/September 2026

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025